Lead Product(s) : K-679
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
K-679 Unimicelle Drug Shows Efficacy in EGFR-Positive Solid Tumors
Details : K-679 is a novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs.
Product Name : K-679
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 21, 2025
Lead Product(s) : K-679
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Candidate was discovered using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) and demonstrated potent and selective GPC3 binding, rapid cellular internalization and sustained tumor specific uptake and anti-tumor efficacy in pre-clini...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 22, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HTL0039732
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Cancer Research
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the Clinical Trial and Licence Agreement (CTLA), Cancer Research UK’s Centre for Drug Development will sponsor, design and execute a Phase I/IIa clinical trial of HTL00397322, a novel selective EP4 antagonist.
Product Name : HTL0039732
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 22, 2022
Lead Product(s) : HTL0039732
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Cancer Research
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Sapanisertib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Calithera Biosciences
Deal Size : $45.0 million
Deal Type : Acquisition
Details : Takeda to acquire two clinical-stage compounds, sapanisertib (CB-228, formerly TAK-228) and mivavotinib (CB-659, formerly TAK-659), both of which have demonstrated single-agent clinical activity with the greatest potential in biomarker-defined cancerpat...
Product Name : CB-228
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
October 18, 2021
Lead Product(s) : Sapanisertib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Calithera Biosciences
Deal Size : $45.0 million
Deal Type : Acquisition
Lead Product(s) : LIV-2008
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Henlius
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Henlius Has Reached an Exclusive License Agreement with Chiome for Antibodies Targeting Human TROP2
Details : Chiome agreed to grant Henlius an exclusive right and license to antibodies targeting human TROP2 and related intellectual property rights to research, develop, manufacture and commercialize the Licensed Products in China.
Product Name : LIV-2008
Product Type : Antibody
Upfront Cash : Undisclosed
January 14, 2021
Lead Product(s) : LIV-2008
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Henlius
Deal Size : Undisclosed
Deal Type : Licensing Agreement